8.68
price down icon8.82%   -0.84
after-market After Hours: 8.82 0.14 +1.61%
loading
Dyne Therapeutics Inc stock is traded at $8.68, with a volume of 9.32M. It is down -8.82% in the last 24 hours and down -27.42% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$9.52
Open:
$8.73
24h Volume:
9.32M
Relative Volume:
3.58
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-2.4382
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
-18.34%
1M Performance:
-27.42%
6M Performance:
-63.16%
1Y Performance:
-75.54%
1-Day Range:
Value
$8.41
$9.23
1-Week Range:
Value
$8.41
$10.74
52-Week Range:
Value
$6.36
$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name
Name
Dyne Therapeutics Inc
Name
Phone
(781) 786-8230
Name
Address
1560 TRAPELO ROAD, WALTHAM
Name
Employee
192
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
DYN's Discussions on Twitter

Compare DYN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DYN
Dyne Therapeutics Inc
8.68 1.68B 0 -294.51M -244.42M -3.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-11-25 Resumed Raymond James Outperform
Jun-02-25 Resumed Oppenheimer Outperform
May-29-25 Initiated Evercore ISI Outperform
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-13-24 Initiated Robert W. Baird Outperform
Nov-26-24 Initiated RBC Capital Mkts Outperform
Oct-24-24 Downgrade JP Morgan Overweight → Neutral
May-21-24 Reiterated Chardan Capital Markets Buy
Apr-30-24 Initiated Morgan Stanley Overweight
Feb-20-24 Initiated H.C. Wainwright Buy
Feb-27-23 Upgrade Raymond James Outperform → Strong Buy
Feb-15-23 Initiated Oppenheimer Outperform
Jan-26-23 Initiated Guggenheim Buy
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Outperform
Oct-12-20 Initiated JP Morgan Overweight
Oct-12-20 Initiated Jefferies Buy
Oct-12-20 Initiated Piper Sandler Overweight
Oct-12-20 Initiated Stifel Buy
View All

Dyne Therapeutics Inc Stock (DYN) Latest News

pulisher
Jun 18, 2025

Dyne Therapeutics (DYN) Receives Continued Buy Rating from Guggenheim | DYN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade (DYN) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics (DYN): Baird Lowers Price Target to $32 | DYN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne at ‘attractive entry point’ following pullback, says Chardan - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne Therapeutics (DYN) Price Target Reduced by Baird | DYN Stoc - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright reiterates buy rating on Dyne Therapeutics stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Dyne adjusts regulatory timeline for DYNE-101 after FDA feedback - The Pharma Letter

Jun 18, 2025
pulisher
Jun 17, 2025

Dyne’s DM1 treatment receives FDA breakthrough designation By Investing.com - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revi - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – DYN - Business Wire

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Stock Price, Quotes and Forecasts - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Boosted by DYNE-101 Program Updates | DY - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Rating and Price Target Maintained by Ch - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | D - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathw - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Transcript : Dyne Therapeutics, Inc.Special Call - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Advances DYNE-101 Program with FDA Pathway Update | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Faces Setback with DYNE-101 Approval Del - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop 18% Amid Trial Endpoint Revision | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Shares Drop Amid Clinical Trial Revision | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Alters Primary Endpoint in Key Study | DYN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne stock on revised plan for clinical program (DYN:NASDAQ) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics (DYN) Gains FDA Breakthrough Therapy Designati - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Granted Breakthrough Therapy Designation - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting - The Manila Times

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Submits Revised ACHIEVE Trial Protocol Elevating vHOT as Primary Endpoint for U.S. Accelerated Approval of DYNE-101 in Myotonic Dystrophy Type 1 - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Dyne Therapeutics Announces FDA Breakthrough Therapy - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

FDA Breakthrough: Dyne's DM1 Drug Shows 20% Muscle Strength Gain in Latest Trial Data - Stock Titan

Jun 17, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics To Host Investor Conference Call And Webcast - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET | DYN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET - GlobeNewswire

Jun 16, 2025
pulisher
Jun 16, 2025

Dyne Therapeutics to Reveal Crucial Data on DYNE-101 DM1 Treatment: Key Clinical Updates Coming Tomorrow - Stock Titan

Jun 16, 2025
pulisher
Jun 12, 2025

Facioscapulohumeral Muscular Dystrophy Pipeline 2025: FDA - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at Raymond James - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Dyne Therapeutics (DYN) Receives "Outperform" Rating by Raymond James | DYN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Dyne Therapeutics (DYN): Analyst Sets Positive Outlook with $37 Price Target | DYN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics officer sells shares worth $1,949 By Investing.com - Investing.com Canada

Jun 06, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics officer sells shares worth $1,949 - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView

Jun 06, 2025
pulisher
Jun 06, 2025

Millennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics to Present New Preclinical Data in - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Dyne Therapeutics (DYN) Unveils Promising Preclinical Data on DY - GuruFocus

Jun 05, 2025

Dyne Therapeutics Inc Stock (DYN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Cap:     |  Volume (24h):